Clinical Trial Update: A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations [Phase 2]

View source ↗

Summary

A Phase 2 randomized crossover trial in untreated EGFR-mutant stage IIIB/IV lung adenocarcinoma compares erlotinib with docetaxel/cisplatin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Tarceva (erlotinib)
• Taxotere (docetaxel)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Neoplasms, Lung, Carcinoma, Non-Small Cell Lung | Phase 2 | Status: UNKNOWN